宁肠饮联合奥沙利铂及卡培他滨治疗结肠癌术后患者的临床观察  

Clinical Observation of Ningchangyin Combined with Oxaliplatin and Capecitabine in the Treatment of Patients with Colon Cancer

作　　者：戚晶 QI Jing(Department of Oncology,Fushun Hospital of Traditional Chinese Medicine,Fushun 113000,China)

机构地区：[1]抚顺市中医院肿瘤科,辽宁抚顺113000

出　　处：《中国医药指南》2018年第31期14-15,共2页Guide of China Medicine

摘　　要：目的观察宁肠饮联合奥沙利铂和卡培他滨治疗结肠癌术后患者的临床疗效。方法选取自2016年1月至2017年1月于我院收治的结肠癌术后接受辅助化疗的患者60例,采用信封法随机分为试验组和对照组,其中对照组30例,采用奥沙利铂联合卡培他滨口服,试验组30例,在对照组的基础上应用中药复方宁肠饮口服。结果试验组的血液学毒性及中医证候评分均优于对照组,有统计学差异(P<0.05)。结论宁肠饮联合奥沙利铂和卡培他滨治疗结肠癌术后患者可以降低患者的血液学毒性,提高患者的中医证候评分,提高生活质量。Objective To observe the clinical efficacy of combined treatment of colon cancer with colon cancer after the treatment of Ningchangyin combined with oxaliplatin and capecitabine.Methods From January 2016 to January 2017 in our hospital 60 cases of colorectal cancer received postoperative adjuvant chemotherapy patients were randomly divided into experimental group and control group using the envelope method,of which 30 cases of the control group,with oxaliplatin combined with capecitabine,30 cases of experimental group,the application of traditional Chinese medicine compound Ningchangyin oral based on control the group.Results The hematological toxicity and TCM syndrome score of the experimental group were better than those of the control group,with statistical difference(P<0.05).Conclusion Ningchangyin can reduce hematological toxicity and improve the quality of life.

关 键 词：宁肠饮 结肠癌 血液学毒性 中医证候积分 

分 类 号：R735.35[医药卫生—肿瘤]